



## Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

December 7, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 7, 2017-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 P.M. ET in New York.

A live webcast of the presentation can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

### About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171207006259/en/>

Source: Sage Therapeutics

### Investor Contact:

Sage Therapeutics  
Paul Cox, 617-299-8377  
[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

### Media Contact:

Suda Communications LLC  
Maureen L. Suda, 585-387-9248  
[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)